Barclays’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-2,300
| Closed | -$17K | – | 5530 |
|
|
2021
Q4 | $17K | Hold |
2,300
| – | – | ﹤0.01% | 3962 |
|
|
2021
Q3 | $21K | Hold |
2,300
| – | – | ﹤0.01% | 4380 |
|
|
2021
Q2 | $28K | Hold |
2,300
| – | – | ﹤0.01% | 4393 |
|
|
2021
Q1 | $29K | Sell |
2,300
-4,100
| -64% | -$55.2K | ﹤0.01% | 4306 |
|
|
2020
Q4 | $100K | Hold |
6,400
| – | – | ﹤0.01% | 4137 |
|
|
2020
Q3 | $60K | Sell |
6,400
-10,200
| -61% | -$110K | ﹤0.01% | 4504 |
|
|
2020
Q2 | $149K | Sell |
16,600
-18,300
| -52% | -$170K | ﹤0.01% | 4275 |
|
|
2020
Q1 | $222K | Sell |
34,900
-12,600
| -27% | -$93.5K | ﹤0.01% | 4217 |
|
|
2019
Q4 | $398K | Sell |
47,500
-1,600
| -3% | -$14.7K | ﹤0.01% | 4490 |
|
|
2019
Q3 | $444K | Buy |
49,100
+8,400
| +21% | +$94.2K | ﹤0.01% | 4342 |
|
|
2019
Q2 | $438K | Sell |
40,700
-5,300
| -12% | -$56.4K | ﹤0.01% | 4437 |
|
|
2019
Q1 | $439K | Sell |
46,000
-30,600
| -40% | -$313K | ﹤0.01% | 4240 |
|
|
2018
Q4 | $879K | Buy |
76,600
+1,500
| +2% | +$18.6K | ﹤0.01% | 3255 |
|
|
2018
Q3 | $1.27M | Sell |
75,100
-107,100
| -59% | -$1.63M | ﹤0.01% | 3394 |
|
|
2018
Q2 | $2.59M | Buy |
182,200
+150,200
| +469% | +$2.49M | ﹤0.01% | 2323 |
|
|
2018
Q1 | $608K | Buy |
32,000
+10,900
| +52% | +$233K | ﹤0.01% | 3759 |
|
|
2017
Q4 | $346K | Sell |
21,100
-13,000
| -38% | -$193K | ﹤0.01% | 4204 |
|
|
2017
Q3 | $512K | Sell |
34,100
-29,000
| -46% | -$321K | ﹤0.01% | 3600 |
|
|
2017
Q2 | $555K | Buy |
63,100
+38,100
| +152% | +$244K | ﹤0.01% | 3415 |
|
|
2017
Q1 | $130K | Sell |
25,000
-7,600
| -23% | -$30.5K | ﹤0.01% | 4693 |
|
|
2016
Q4 | $99K | Buy |
32,600
+3,000
| +10% | +$10.9K | ﹤0.01% | 4753 |
|
|
2016
Q3 | $137K | Buy |
29,600
+25,500
| +622% | +$130K | ﹤0.01% | 4277 |
|
|
2016
Q2 | $24K | Buy |
4,100
+3,200
| +356% | +$20.4K | ﹤0.01% | 5201 |
|
|
2016
Q1 | $5K | Sell |
900
-11,700
| -93% | -$70.3K | ﹤0.01% | 5677 |
|
|
2015
Q4 | $113K | Buy |
12,600
+7,800
| +163% | +$60.1K | ﹤0.01% | 4329 |
|
|
2015
Q3 | $24K | Sell |
4,800
-25,700
| -84% | -$212K | ﹤0.01% | 5373 |
|
|
2015
Q2 | $336K | Sell |
30,500
-21,800
| -42% | -$281K | ﹤0.01% | 3784 |
|
|
2015
Q1 | $785K | Buy |
52,300
+9,700
| +23% | +$150K | ﹤0.01% | 3190 |
|
|
2014
Q4 | $639K | Buy |
42,600
+8,800
| +26% | +$107K | ﹤0.01% | 3623 |
|
|
2014
Q3 | $338K | Buy |
33,800
+9,200
| +37% | +$120K | ﹤0.01% | 4296 |
|
|
2014
Q2 | $369K | Sell |
24,600
-294,600
| -92% | -$4.24M | ﹤0.01% | 4268 |
|
|
2014
Q1 | $5.75M | Buy |
319,200
+15,300
| +5% | +$295K | 0.01% | 1595 |
|
|
2013
Q4 | $3.95M | Buy |
303,900
+255,800
| +532% | +$2.95M | ﹤0.01% | 2022 |
|
|
2013
Q3 | $481K | Buy |
48,100
+12,100
| +34% | +$120K | ﹤0.01% | 4161 |
|
|
2013
Q2 | $282K | Buy |
+36,000
| New | +$314K | ﹤0.01% | 4843 |
|
Other funds holding SGMO
AC
VCM
VFT
Barclays's SGMO Position: Q1 2026 in Review
Barclays held its SANGAMO THERAPEUTICS INC (SGMO) position steady in Q1 2026 at 1 share worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #5385.
Barclays first reported a position in SGMO in Q2 2013 and has held it in 52 quarters since. The position peaked at $5.28M in Q4 2020. 112 funds tracked by Wall St. Rank hold SGMO as of Q1 2026.
- Barclays held 1 share of SANGAMO THERAPEUTICS INC worth $0 as of Q1 2026.
- Barclays left its SANGAMO THERAPEUTICS INC share count unchanged in Q1 2026.
- SANGAMO THERAPEUTICS INC made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #5385 holding.
- Barclays first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 52 quarters since.
- Barclays's SANGAMO THERAPEUTICS INC position peaked at $5.28M in Q4 2020.
- 112 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.